Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

FDA clears Tonix IND in major depressive disorder

The FDA approved Tonix Pharmaceuticals’ (NASDAQ:TNXP) IND application to support a Phase 2 clinical trial with TNX-601 ER, a once-daily formulation of tianeptine as a potential treatment for major depressive disorder...

October 3, 2022

Developments

Pieter Cullis wins 2022 Bloom Burton Award

Pieter Cullis, co-founder and chairman of closely-held Acuitas Therapeutics is the recipient of the 2022 Bloom Burton Award, given annually to honor an individual who made the greatest contribution to Canada’s...

September 30, 2022

Markets

Maxim ups Fennec PT to $15 on PEDMARK approval

Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of...

September 29, 2022

Markets

Cantor starts Cognition at OW; PT $12

Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...

September 29, 2022

Markets

WB starts Akouos at OP; fair value estimate $12

William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...

September 29, 2022

Developments

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

VoxNeuro, a closely-held software-as-a-medical-device (SaMD) brain health company, has partnered with the Canadian Armed Forces (CAF) to study the cognitive effects following intense military training regimens designed...

September 28, 2022

Markets

Stifel cuts PhaseBio to hold on bentracimab ownership dispute

Stifel downgraded PhaseBio Pharmaceuticals (NASDAQ:PHAS) to “hold” from “buy” and slashed its price target to $1 from $15, citing an ownership dispute over PhaseBio’s bentracimab, a potential ticagrelor reversal agent...

September 28, 2022

Developments

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

EmpathBio, a unit of atai Life Sciences (NASDAQ:ATAI), received regulatory and ethics approval to begin enrollment of its Phase 1 study of EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment...

September 28, 2022

Developments

SAB Biotherapeutics presents new influenza and COVID-19 data

SAB Biotherapeutics (NASDAQ:SABS) presented new data at the Options for Control of Influenza conference in Belfast, showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants...

September 28, 2022

Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022

Developments

Maxim survey finds two-thirds of respondents planning to attend JMP

A survey of 150 people to a recent Maxim Group survey about the upcoming J.P. Morgan Healthcare Conference found that 69% of respondents are planning to attend the conference in person, while 52% would choose in person...

September 26, 2022

Developments

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

An investigator for Profound Medical (NASDAQ:PROF; TSX:PRN) presented four-year follow-up data from the TACT clinical study with Profound’s TULSA-PRO device that continue to demonstrate durable and stable safety and...

September 26, 2022

FDA clears Tonix IND in major depressive disorder

Pieter Cullis wins 2022 Bloom Burton Award

Maxim ups Fennec PT to $15 on PEDMARK approval

Cantor starts Cognition at OW; PT $12

WB starts Akouos at OP; fair value estimate $12

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

Stifel cuts PhaseBio to hold on bentracimab ownership dispute

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

SAB Biotherapeutics presents new influenza and COVID-19 data

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim survey finds two-thirds of respondents planning to attend JMP

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

General

More